MX2010001416A - Compuesto para el tratamiento de la hepatitis c. - Google Patents

Compuesto para el tratamiento de la hepatitis c.

Info

Publication number
MX2010001416A
MX2010001416A MX2010001416A MX2010001416A MX2010001416A MX 2010001416 A MX2010001416 A MX 2010001416A MX 2010001416 A MX2010001416 A MX 2010001416A MX 2010001416 A MX2010001416 A MX 2010001416A MX 2010001416 A MX2010001416 A MX 2010001416A
Authority
MX
Mexico
Prior art keywords
compounds
hepatitis
treatment
hcv
virus
Prior art date
Application number
MX2010001416A
Other languages
English (en)
Spanish (es)
Inventor
Carl P Bergstrom
Scott W Martin
Robert G Gentles
Kap-Sun Yeung
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2010001416A publication Critical patent/MX2010001416A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2010001416A 2007-08-09 2008-08-01 Compuesto para el tratamiento de la hepatitis c. MX2010001416A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US95481407P 2007-08-09 2007-08-09
US4994408P 2008-05-02 2008-05-02
US12/180,994 US7652004B2 (en) 2007-08-09 2008-07-28 Compounds for the treatment of hepatitis C
PCT/US2008/071881 WO2009029384A2 (en) 2007-08-09 2008-08-01 Compounds for the treatment of hepatitis c

Publications (1)

Publication Number Publication Date
MX2010001416A true MX2010001416A (es) 2010-03-01

Family

ID=40261456

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001416A MX2010001416A (es) 2007-08-09 2008-08-01 Compuesto para el tratamiento de la hepatitis c.

Country Status (18)

Country Link
US (1) US7652004B2 (https=)
EP (1) EP2183252B1 (https=)
JP (1) JP5465670B2 (https=)
KR (1) KR20100066492A (https=)
CN (1) CN101821267B (https=)
AR (1) AR067897A1 (https=)
AU (1) AU2008293845B2 (https=)
BR (1) BRPI0814931A2 (https=)
CA (1) CA2695781A1 (https=)
CL (1) CL2008002353A1 (https=)
CO (1) CO6251359A2 (https=)
EA (1) EA015978B1 (https=)
MX (1) MX2010001416A (https=)
NZ (1) NZ583149A (https=)
PE (1) PE20090618A1 (https=)
TW (1) TW200906418A (https=)
WO (1) WO2009029384A2 (https=)
ZA (1) ZA201000923B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049622A1 (ja) * 2003-11-19 2005-06-02 Japan Tobacco Inc. ５－５員縮合複素環化合物及びそのｈｃｖポリメラーゼ阻害剤としての用途
US20070049593A1 (en) * 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
KR20100108341A (ko) * 2007-11-20 2010-10-06 브리스톨-마이어스 스큅 컴퍼니 시클로프로필 융합된 인돌로벤즈아제핀 ｈｃｖ ｎｓ5ｂ 억제제
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
KR20100124848A (ko) 2008-03-27 2010-11-29 브리스톨-마이어스 스큅 컴퍼니 방향족 헤테로시클릭 융합된 인돌로벤자디아제핀 ｈｃｖ ｎｓ5ｂ 억제제
US8133884B2 (en) * 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
JP2012517468A (ja) * 2009-02-11 2012-08-02 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎治療のための化合物
CA2822357A1 (en) 2010-12-22 2012-06-28 Abbvie Inc. Hepatitis c inhibitors and uses thereof
CH706864B1 (de) 2011-06-22 2016-03-31 Central Glass Co Ltd Verfahren zur Herstellung einer Pyrazol-Verbindung.
JP5915004B2 (ja) * 2011-06-22 2016-05-11 セントラル硝子株式会社 ピラゾール化合物の製造方法
EP3091022A3 (en) * 2012-07-18 2016-12-14 Bristol-Myers Squibb Holdings Ireland Methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3- methoxy-5a-((1r,5s)-3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20090250T1 (hr) 2004-02-24 2009-06-30 Japan Tobacco Kondenzirani heterociklički spojevi i njihova upotreba kao inhibitora hcv polimeraze
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
EP1807403A2 (en) 2004-10-26 2007-07-18 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Tetracyclic indole derivatives as antiviral agents
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) * 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) * 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7456166B2 (en) * 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) * 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
JP5205370B2 (ja) * 2006-05-25 2013-06-05 ブリストル−マイヤーズ スクイブ カンパニー シクロプロピル縮合インドロベンゾアゼピンｈｃｖｎｓ５ｂ阻害剤
WO2007140200A2 (en) * 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US7452876B2 (en) * 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7541351B2 (en) * 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) * 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538102B2 (en) * 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7521444B2 (en) * 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7541353B2 (en) * 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7547690B2 (en) * 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7538103B2 (en) * 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C

Also Published As

Publication number Publication date
US7652004B2 (en) 2010-01-26
AR067897A1 (es) 2009-10-28
AU2008293845B2 (en) 2013-02-14
AU2008293845A1 (en) 2009-03-05
EA015978B1 (ru) 2012-01-30
CO6251359A2 (es) 2011-02-21
US20090074715A1 (en) 2009-03-19
WO2009029384A2 (en) 2009-03-05
JP2010535787A (ja) 2010-11-25
ZA201000923B (en) 2011-04-28
EP2183252A2 (en) 2010-05-12
EA201000277A1 (ru) 2010-06-30
PE20090618A1 (es) 2009-05-16
KR20100066492A (ko) 2010-06-17
WO2009029384A3 (en) 2009-05-28
CN101821267B (zh) 2013-07-10
EP2183252B1 (en) 2015-01-14
JP5465670B2 (ja) 2014-04-09
CL2008002353A1 (es) 2008-10-24
NZ583149A (en) 2011-07-29
CA2695781A1 (en) 2009-03-05
TW200906418A (en) 2009-02-16
CN101821267A (zh) 2010-09-01
BRPI0814931A2 (pt) 2015-02-03

Similar Documents

Publication Publication Date Title
SI1987038T1 (sl) Hcv ns5b inhibitorji
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
ATE469155T1 (de) Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer
ATE522532T1 (de) Verbindungen zur behandlung von hepatitis c
SI2209789T1 (sl) Ciklopropil zliti indolobenzazepin hcv ns5b inhibitorji
MX2012004032A (es) Compuestos para el tratamiento de hepatitis c.
TW200745120A (en) Indolobenzazepine HCV NS5B inhibitors
DE602008004317D1 (de) Verbindungen zur behandlung von hepatitis c
ATE551343T1 (de) Tetracyclische verbindungen zur behandlung von hepatitis c
WO2007140200A3 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
WO2010030538A3 (en) Compounds for the treatment of hepatitis c
MY152070A (en) Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
EA200900298A1 (ru) Ингибиторы вируса гепатита с
ATE505473T1 (de) Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c
MX2010008749A (es) Inhibidores del virus de la hepatitis c.
IL195025A (en) History of compressed indolubenzazepine with cyclopropyl and pharmaceuticals containing them as an anti-hcv drug
EA201001275A1 (ru) Конформационно-ограниченные бифенильные производные для применения в качестве ингибиторов вируса гепатита с
MX2011009644A (es) Inhibidores del virus de la hepatitis c.
EA201270656A1 (ru) Ингибиторы вируса гепатита с
EA201101082A1 (ru) Ингибиторы вируса гепатита с
MX2011006631A (es) Inhibidores de proteasa ns3 del virus hcv.
MX2013002927A (es) Inhibidores del virus de la hepatitis c.
MX2010010061A (es) Compuestos para el tratamiento de hepatitis c.
MX2010010235A (es) Inhibidores de ns5b de virus de la hepatitis c de indolobenzadiazepina fusionados a pirrolidina.

Legal Events

Date Code Title Description
FG Grant or registration